Aspirin and heparin in acute ischaemic stroke in older patients.
Over four-fifths of all strokes are due to thrombotic or embolic occlusion of cerebral arteries. There is a strong rationale for considering antithrombotic therapy for the treatment of patients with acute ischaemic stroke. Antiplatelet therapy with 150 to 300mg of aspirin (acetylsalicylic acid) star...
| Publicado en: | Drugs & Aging Vol. 15; no. 1; pp. 29 - 37 |
|---|---|
| Autores principales: | , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
1999
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106100690&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 106100690 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1170229X C5B jtl: Drugs & Aging issn: 1170229X maglogo: N pubinfo: dt: 1999 vid: 15 iid: 1 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 106100690 2009465436 NLM10459730 106100690 ppf: 29 ppct: 8 formats: fmt: @attributes: type: P tig: atl: Aspirin and heparin in acute ischaemic stroke in older patients. aug: au: Gubitz G Sandercock P sug: subj: Anticoagulants Therapeutic Use Aspirin Therapeutic Use Cerebral Ischemia Drug Therapy Heparin, Low-Molecular-Weight Therapeutic Use Platelet Aggregation Inhibitors Therapeutic Use Acute Disease Aged Anticoagulants Adverse Effects Aspirin Adverse Effects Cerebral Hemorrhage Chemically Induced Cerebral Ischemia Prevention and Control Cerebrovascular Disorders Prevention and Control Geriatrics Heparin, Low-Molecular-Weight Adverse Effects Platelet Aggregation Inhibitors Adverse Effects Aged: 65+ years ab: Over four-fifths of all strokes are due to thrombotic or embolic occlusion of cerebral arteries. There is a strong rationale for considering antithrombotic therapy for the treatment of patients with acute ischaemic stroke. Antiplatelet therapy with 150 to 300mg of aspirin (acetylsalicylic acid) started within the first 48 hours of an ischaemic stroke improves patient outcome in the short and long term, with a low risk of adverse effects. Anticoagulants such as heparin may reduce the risk of developing deep venous thrombosis and pulmonary embolism in patients with stroke, but randomised controlled trials have demonstrated a significant and dose-dependent risk of intracranial haemorrhage. The routine use of parenteral anticoagulants, including unfractionated heparin, low-molecular-weight heparins and heparinoids in the acute phase of ischaemic stroke is not associated with any net short or long term benefit. Aspirin is, therefore, the antithrombotic drug of choice in the treatment of acute ischaemic stroke. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|